New drug combo shows safety promise for tough breast cancer
NCT ID NCT05631795
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 28 times
Summary
This study tested the safety of two drugs, alpelisib and fulvestrant, in 40 men and postmenopausal women with a specific type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) that had worsened after hormone therapy. The goal was to see how many people had side effects during treatment. Results help doctors understand the risks of this combination for controlling the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Guwahati, Assam, 781016, India
-
Novartis Investigative Site
Surat, Gujarat, 395009, India
-
Novartis Investigative Site
Thalassery, Kerala, 670103, India
-
Novartis Investigative Site
Trivandrum, Kerala, 695 011, India
-
Novartis Investigative Site
Bhopal, Madhya Pradesh, 462001, India
-
Novartis Investigative Site
Mumbai, Maharashtra, 400 012, India
-
Novartis Investigative Site
Nagpur, Maharashtra, 440001, India
-
Novartis Investigative Site
Pune, Maharashtra, 411040, India
-
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110029, India
-
Novartis Investigative Site
Hyderabad, Telangana, 500004, India
-
Novartis Investigative Site
Ahmedabad, 380016, India
-
Novartis Investigative Site
Kolkata, 700026, India
Conditions
Explore the condition pages connected to this study.